Abstract LB-216: NCI 9455: Phase II study of trametinib followed by trametinib plus AKT inhibitor,GSK2141795 in patients with advanced triple negative breast cancer

Bhuvaneswari Ramaswamy(The Ohio State University), William E. Carson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Mahmoud Abdel‐Rasoul(The Ohio State University), Robert Wesolowski(The Ohio State University Wexner Medical Center), Cynthia Timmers(Cancer Genetics (United States)), Miguel A. Villalona(Cancer Institute of Florida), Ewa Mrózek(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Erin Macrae(McGill University), Charles L. Shapiro(Tisch Hospital), Helen Chen(IQVIA (United States)), Rachel M. Layman(The University of Texas MD Anderson Cancer Center), Claudine Isaacs(Georgetown University), Andrew Poklepovic(Virginia Commonwealth University), Claire Dees(University of North Carolina at Chapel Hill), Maryam B. Lustberg(Yale Cancer Center), Robyn Patrick(The Ohio State University), Thomas Budd(Cleveland Clinic), Micheal R. Grever(Ohio University), Roohi Ismail‐Khan(Moffitt Cancer Center), Jennifer Sexton(Ohio University), Lyndsay N. Harris(National Institutes of Health)
Cancer Research
July 15, 2016
Cited by 15


Related Papers